Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer to sell selected...

    Bayer to sell selected crop science biz to BASF for 7 billion dollar

    Written by Ruby Khatun Khatun Published On 2017-10-15T09:21:13+05:30  |  Updated On 15 Oct 2017 9:21 AM IST
    Bayer to sell selected crop science biz to BASF for 7 billion dollar

    New Delhi: German drug and agrochemicals major Bayer on Friday announced the sale of selected crop science businesses to BASF for USD 7 billion as part of its strategy to complete the acquisition of US biotech major Monsanto.


    However, the company said that this deal will have no impact on Bayer's India business.


    "In light of the planned acquisition of Monsanto, Bayer has signed an agreement to sell selected Crop Science businesses to BASF for EUR 5.9 billion," Bayer said in a statement.


    The assets to be sold generated net sales of about EUR 1.3 billion in 2016.


    Separately, Germany-based BASF -- the world's third- largest crop chemicals manufacturer -- said it has signed an agreement to acquire significant parts of Bayer's seed and non-selective herbicide businesses.


    The transaction is subject to regulatory approvals and the successful closing of Bayer s acquisition of Monsanto.


    "We are taking an active approach to address potential regulatory concerns, with the goal of facilitating a successful close of the Monsanto transaction," said Werner Baumann, Chairman of the Board of Management of Bayer AG.


    Bayer said it will continue to work diligently with the relevant authorities with the aim of closing the planned acquisition of Monsanto by early 2018.


    Bayer had in September 2016 agreed to take over the American seeds major Monsanto for USD 66 billion


    The assets to be sold include Bayer's global glufosinate-ammonium business and the related LibertyLink technology for herbicide tolerance, essentially all of the company s field crop seeds businesses, as well as respective research and development capabilities.


    "The seeds businesses being divested include the global cotton seed business (excluding India and South Africa), the North American and European canola seed businesses and the soybean seed business," Bayer said.


    The transaction includes the transfer of relevant intellectual property and facilities, as well as more than 1,800 employees primarily in the US, Germany, Brazil, Canada, and Belgium.

    AcquisitionBASFBayerherbicideMonsantoselected crop sciencesellWerner Baumann
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok